Under the terms of the agreement, ITM will supply its therapeutic medical radioisotope, Ac-225, produced by Actineer TM Inc. (Actineer), the joint venture between ITM and Canadian Nuclear ...

AC-225 is suitable for applications with up to 30,000 users across a modular 2,000 doors, allowing maximum flexibility for securing a growing enterprise. Each AC-225 Access Control Unit (ACU) supports ...

This publication includes existing experiences, lessons learned, challenges and future developments in the production of Ac-225 radiopharmaceuticals for Targeted Alpha Therapy (TAT). This publication ...

Under the terms of the agreement, ITM will supply its therapeutic medical radioisotope, Ac-225, produced by Actineer Inc. (Actineer), the joint venture between ITM and Canadian Nuclear Laboratories.

Actinium leads the industry in the application of the alpha-particle emitter actinium-225 (Ac-225), which is the most potent medical-grade radioisotope currently available. Its radiation power is ...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today initiation of a Phase I clinical trial with 225 Ac-GPC3 (BAY 3547926), an investigational targeted alpha radiopharmaceutical being developed ...

Under the terms of the agreement, ITM will supply its therapeutic medical radioisotope, Ac-225, produced by Actineer TM Inc. (Actineer), the joint venture between ITM and Canadian Nuclear Laboratories ...